靶向RNAi抑制survivin基因增强胰腺癌对厄洛替尼化疗敏感性的实验研究  

Experimental study of targeting RNA interference inhibition of survivin gene enhance chemosensitivity of erlotinib in pancreatic cancer PANC-1 cells

作　　者：陈俭云[1] 王正文[2] 崔海宁[2] 罗健[1] 

机构地区：[1]广东省深圳市第五人民医院/罗湖医院普通外科,广东深圳518001 [2]海南医学院附属医院普通外科,海南海口570102

出　　处：《海南医学院学报》2013年第8期1019-1022,共4页Journal of Hainan Medical University

基　　金：海南省卫生厅重点科研课题(批准号:琼卫2010重点-14);深圳市科技计划项目(批准号:201202184)资助~~

摘　　要：目的:胰腺癌的化疗药物耐药是一个亟待解决的问题。存活素(survivin)基因是肿瘤化疗耐药的重要原因。运用RNAi载体抑制survivin的表达对增强胰腺癌对厄洛替尼敏感性的影响。为增强胰腺癌化疗敏感性奠定一定的实验基础。方法:培养胰腺癌细胞PANC-1,构建以U6为启动子的RNAi载体并转染PANC-1,运用FCM检测加入厄洛替尼前后胰腺癌细胞凋亡指数和Hoechest 33258检测凋亡形态,MTT检测转染前后IC50。结果:转染survivin的RNAi载体后48h,流式细胞仪检测的凋亡指数为15.24%±1.35%,与对照组比较差异有显著性(P<0.05);Hoechst33258染色显示,PANC-1细胞出现核皱缩、浓染和碎裂等典型的凋亡形态,MTT检测转染前及转染后48h厄洛替尼的IC50分别为(1.35±0.05)μg/mL,(0.46±0.08)μg/mL,与对照组比较差异有显著性(P<0.05)。结论:Sur-vivin的RNAi载体,能有效地增强胰腺癌对厄洛替尼的化疗敏感性。Objective： Using RNAi vectors to inhibit the expression of survivin and enhance the chemosensitivity of erlotinib in pancreatic cancer PANC-1 cells. Methods： Pancreatic cancer cells were cul- tured, RNAi with vectors U6 promoter were constructed and PANC-1 transfected. And pancreatic cancer cell apoptosis index were detected by FCM detection, and apoptotic morphology were detected by Hoechest 33258 before and after transfection. IC50 were detected by MTT assay. Results： Forty hours post transection, apoptosis index was （15.24 ± 1.35） %, significant different from that of the control group （P〈0.05）; Hoechst 33258 staining showed PANC-1 cells nuclear shrinkage, stain and fragmentation typical apoptotic morphology, MTT assay showed IC50 of erlotinih were （1.35±0.05） μg/mL,and （0.46±0. 08） μg/mL 48 hours after transfeetion which was significant different from that of the control group （P〈3.05）. Conclusion： Survivin RNAi vectors can effectively enhance the chemosensitivity of erlotinib in pan- creatic carcinoma.

关 键 词：胰腺癌 存活素(survivin) RNA干扰(RNAI) 厄洛替尼 化疗敏感性 

分 类 号：R73[医药卫生—肿瘤]